Nuformix PLC Dr Chris Blackwell Appointed NED (7341N)
May 11 2018 - 2:31AM
UK Regulatory
TIDMNFX
RNS Number : 7341N
Nuformix PLC
11 May 2018
Nuformix plc
("Nuformix" or "the Company")
Board Announcement
Nuformix appoints Dr Chris Blackwell as Non-executive
Director
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs today announced that it has appointed Dr Christopher
Blackwell as a Non-executive Director. The appointment reflects
Nuformix's ambition and trajectory as it embarks on a period of
growth, building on its position of developing innovative
cocrystal-based therapies. Chris joins the Board with immediate
effect.
Dr Chris Blackwell, B.Sc, Ph.D. served as CEO of Vectura Group
Plc from February 2004 to June 2015, taking the company through its
initial IPO to a valuation of over $1 billion. Chris presided over
a period of significant growth including deal-making (including a
$375m out-licensing agreement with Novartis, Europe's largest
biotech deal of 2005), fund-raising, M&A and corporate
development that transformed Vectura's capabilities from research
led technology development to commercially driven pharmaceutical
development. Chris' track record and experience will guide Nuformix
through its next stage of growth.
Chris has also held previous executive roles at Glaxo Group
Research Ltd and Hoffman La-Roche. He also served as Senior
Independent Non-executive Director at AGI Therapeutics Ltd between
July 2006 and February 2012 and is Executive Chairman of Circadian
Therapeutics Ltd.
No further information is required to be disclosed pursuant to
LR 9.6.13 R.
Dr Chris Blackwell, commenting, said: "It's a pleasure to be
joining the Board at this exciting time and to support the
management team with the development of its drug pipeline,
particularly given Nuformix's approach to diseases such as
fibrosis, with its NXP002 programme, targeting large unmet needs in
therapeutic markets with significant commercial potential."
Commenting, Dr Dan Gooding, Chief Executive Officer, Nuformix,
said: "I'm delighted to announce Chris's appointment. He will
provide the Board with invaluable experience in the public markets
and in achieving successful growth as an innovative pharmaceutical
development company. Chris's extensive knowledge and experience are
simply a perfect fit with our corporate development goals and his
arrival demonstrates the impact Nuformix hopes to achieve in the
commercialisation of our product pipeline."
The Company has entered into an agreement with Chris Blackwell
whereby he will be issued with warrants to subscribe for 3,000,000
new ordinary shares of 0.1 pence in the capital of the Company
conditional upon him continuing to act as Non-executive Director of
the Company on 11 May 2019 ("Warrants"). The Warrants are
exercisable from 11 May 2019 to 11 May 2021, at an exercise price
of 4 pence per ordinary share.
Follow Nuformix on Vox Markets: follow at
www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 423667
Gable Communications Ltd
John Bick / Justine James +44 (0)20 7193 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix' risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2009 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFFTEFIILIT
(END) Dow Jones Newswires
May 11, 2018 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2023 to Apr 2024